Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BIO-TECHNE (TECH) Cash & Current Investments: 2009-2025

Historic Cash & Current Investments for BIO-TECHNE (TECH) over the last 17 years, with Jun 2025 value amounting to $165.0 million.

  • BIO-TECHNE's Cash & Current Investments fell 25.36% to $145.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $631.4 million, marking a year-over-year decrease of 2.78%. This contributed to the annual value of $165.0 million for FY2025, which is 2.12% up from last year.
  • Latest data reveals that BIO-TECHNE reported Cash & Current Investments of $165.0 million as of FY2025, which was up 2.12% from $161.6 million recorded in FY2024.
  • BIO-TECHNE's 5-year Cash & Current Investments high stood at $247.0 million for FY2022, and its period low was $161.6 million during FY2024.
  • For the 3-year period, BIO-TECHNE's Cash & Current Investments averaged around $177.0 million, with its median value being $165.0 million (2025).
  • Per our database at Business Quant, BIO-TECHNE's Cash & Current Investments increased by 6.68% in 2022 and then fell by 20.90% in 2024.
  • BIO-TECHNE's Cash & Current Investments (Yearly) stood at $231.6 million in 2021, then rose by 6.68% to $247.0 million in 2022, then dropped by 17.29% to $204.3 million in 2023, then declined by 20.90% to $161.6 million in 2024, then climbed by 2.12% to $165.0 million in 2025.